Low-grade chronic inflammation mediated by mast cells in fibromyalgia

Journal of Biological Regulators and Homeostatic Agents

Volumn 32, Issue 2, 2018, Pages 195-198

  Mastrangelo, F ^a   Frydas, I ^b   Ronconi, G ^c   Kritas, S K ^b   Tettamanti, L ^d   Caraffa, A L ^e   D'Ovidio C ^f   Younes, A ^g   Gallenga, C E ^h   Conti, P ^f  

^a UNIVERSITY OF FOGGIA   (Italy)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY OF CHIETI   (Italy)

^g SPIRITO SANTO HOSPITAL   (Italy)

^h UNIVERSITY OF FERRARA   (Italy)

Author keywords

Erythropoietin; Lipopolysaccharide (LPS); Liver damage; Mitochondria; NLRP3

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; INTERLEUKIN 37; SUBSTANCE P; AUTACOID; IL37 PROTEIN, HUMAN; INTERLEUKIN 1;

ARTICLE; CHRONIC INFLAMMATION; COGNITIVE DEFECT; CYTOKINE RELEASE; DEPRESSION; FATIGUE; FIBROMYALGIA; HUMAN; JOINT STIFFNESS; MAST CELL; NONHUMAN; SLEEP DISORDER; INFLAMMATION; METABOLISM;

FIBROMYALGIA; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1; MAST CELLS;

EID: 85047837237     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Di Tommaso Morrison MC, Carinci F, Lessiani G, et al. Fibromyalgia and bipolar disorder: extent of comorbidity and therapeutic implications. J Biol Regul Homeost Agents 2017; 31(1):17-20.
2. Torgrimson-Ojerio B, Ross RL, Dieckmann NF, et al. Preliminary evidence of a blunted anti-inflammatory response to exhaustive exercise in fibromyalgia. J Neuroimmunol 2014; 277:160-67.
3. Arreola R, Becerril-Villanueva E, Cruz-Fuentes C, et al. Immunomodulatory effects mediated by serotonin. J Immunol Res 2015; 2015:354957.
4. Kopp S. Neuroendocrine, immune, and local responses related to temporomandibular disorders. Kopp S. J Orofac Pain 2001 Winter; 15(1):9-28.
5. Geenen R, Jacobs JW, Bijlsma JW. Evaluation and management of endocrine dysfunction in fibromyalgia. Rheum Dis Clin North Am 2002; 28(2):389-404.
6. Lawson K. Potential drug therapies for the treatment of fibromyalgia. Expert Opin Investig Drugs 2016; 25(9):1071-81.
7. McBeth J, Mulvey MR. Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria. Nat Rev Rheumatol 2012;
8. Borchers AT, Gershwin ME. Fibromyalgia: A Critical and Comprehensive Review Clin Rev Allergy Immunol 2015; 49(2):100-51.
9. Mullington JM, Hinze-Selch D, Pollmächer T. Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions. Ann N Y Acad Sci 2001; 933:201-10.
10. Thompson ME, Barkhuizen A. Fibromyalgia, hepatitis C infection, and the cytokine connection. Curr Pain Headache Rep 2003; 7(5):342-47.
11. Tsilioni I, Russell IJ, Stewart JM, Gleason RM, Theoharides TC. Neuropeptides CRH, SP, HK-1, and Inflammatory Cytokines IL-6 and TNF are increased in serum of patients with fibromyalgia syndrome, implicating mast cells. J Pharmacol Exp Ther 2016; 356(3):664-72.
12. Petra AI, Panagiotidou S, Stewart JM, Conti P, Theoharides TC. Spectrum of mast cell activation disorders. Expert Rev Clin Immunol 2014; 10(6):729-39.
13. Presta I, Guadagno E, Di Vito A, et al. Innate immunity may play a role in growth and relapse of chordoid meningioma. Int J Immunopathol Pharmacol 2017; 30(4):429-33.
14. Cavalli G, Dinarello CA. Suppression of inflammation and acquired immunity by IL-37. Immunol Rev 2018; 281(1):179-90.